Disclosures for "Effects of Semaglutide on Alzheimer’s Disease-related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment"
-
Dr. FREDERIKSEN has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer (Nature). Dr. FREDERIKSEN has received research support from AP Møller Fonden. Dr. FREDERIKSEN has received publishing royalties from a publication relating to health care.
-
Dr. Mystkowski has received personal compensation for serving as an employee of Novo Nordisk. Dr. Mystkowski has stock in Novo Nordisk.
-
Marie Bentsen has received personal compensation for serving as an employee of Novo Nordisk.
-
Dr. Belmont-Rausch has received personal compensation for serving as an employee of Novo Nordisk A/S. Dr. Belmont-Rausch has or had stock in Novo Nordisk.Dr. Belmont-Rausch has or had stock in Viking Therapeutics.Dr. Belmont-Rausch has or had stock in Madrigal Pharmaceuticals.
-
Ms. Carstensen has received personal compensation for serving as an employee of Novo Nordisk A/S. Ms. Carstensen has stock in Novo Nordisk A/S.
-
Mr. Cutler has nothing to disclose.
-
Dr. Farooq has nothing to disclose.
-
Ms. Hildebrandt has received personal compensation for serving as an employee of Novo Nordisk A/S. Ms. Hildebrandt has stock in Novo Nordisk A/S.
-
Marti Jimenez Mausbach has received personal compensation for serving as an employee of Novo Nordisk. Marti Jimenez Mausbach has stock in Novo Nordisk.
-
Dr. Johannsen has received personal compensation for serving as an employee of Novo Nordisk. Dr. Johannsen has or had stock in Novo Nordisk.
-
Dr. Martino has received personal compensation for serving as an employee of Novo Nordisk A/S. Dr. Martino has stock in Novo Nordisk. Dr. Martino has stock in Roche. Dr. Martino has stock in Eli Lilly.
-
Dr. Polex-Wolf has received personal compensation for serving as an employee of Novo Nordisk A/S. Dr. Polex-Wolf has stock in Novo Nordisk.
-
Mrs. Zaratiegui has received personal compensation for serving as an employee of Novo Nordisk A/S. Mrs. Zaratiegui has stock in Novo Nordisk A/S.
-
Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Frisoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk. The institution of Dr. Frisoni has received research support from Novo Nordisk.
-
Dr. Attfield has nothing to disclose.
-
Dr. Knudsen has stock in Novo Nordisk. Dr. Knudsen has received intellectual property interests from a discovery or technology relating to health care.